Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 4/20 | 0.53 |
| ▸ | SCD | O00767 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68730 | 1.00 | SCD5 (0.53) | SCD5SCDNPC1RAB9AKMT2A | |
| SCHEMBL29385678 | 0.86 | HIF1A (0.52) | SCD5NPC1RAB9AKMT2AHIF1A | |
| SCHEMBL69338 | 0.86 | HIF1A (0.52) | SCD5NPC1RAB9AKMT2AHIF1A | |
| SCHEMBL29385107 | 0.86 | HIF1A (0.52) | SCD5NPC1RAB9AKMT2AHIF1A | |
| SCHEMBL69860 | 0.86 | HIF1A (0.52) | SCD5NPC1RAB9AKMT2AHIF1A | |
| SCHEMBL1222168 | 0.84 | SCD5 (0.54) | SCD5SCDNPC1RAB9AKMT2A | |
| SCHEMBL69191 | 0.83 | SCD5 (0.52) | SCD5NPC1RAB9AKMT2AMAPT | |
| SCHEMBL29385676 | 0.83 | SCD5 (0.52) | SCD5NPC1RAB9AKMT2AMAPT | |
| SCHEMBL29381924 | 0.82 | SCD (0.56) | SCDNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL69750 | 0.82 | SCD (0.56) | SCDNPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433880-B2 | Methods for the treatment of neurological disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-07 | — | — | US | disclosed |
| EP-3566055-B1 | SCD INHIBITOR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-12 | — | — | EP | disclosed |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433880-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | SCD5 1591/4885SCD 1194/4885NPC1 356/4885 |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | SCD5 1591/4885SCD 1194/4885NPC1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.